Jobs
View more job listings or post a job
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Horizon Therapeutics Director, Bioanalytical Sciences
Exelixis Principal Scientist - DMPK
Post a job

Workshop

Biotransformation and Disposition of Larger Molecules: Peptides, Nucleotides, Proteins, mAbs, and ADCs


Speakers: Donglu Zhang (Genentech), Mark Cancilla (Merck), Aiming Yu (UC Davis), Jing Li (Alnylam Pharmaceuticals), Fang Xie (Amgen) , Mei Han (Amgen) , Srikanth Kotapat (Bristol-Myers Squibb), Dian Su (Genentech), Ben Shen (Genentech), Divya Samineni (Genentech)Donglu Zhang (Genentech), Mark Cancilla (Merck), Aiming Yu (UC Davis), Jing Li (Alnylam Pharmaceuticals), Fang Xie (Amgen) , Mei Han (Amgen) , Srikanth Kotapat (Bristol-Myers Squibb), Dian Su (Genentech), Ben Shen (Genentech), Divya Samineni (Genentech)
Organizers: Dian Su (Genentech)
Date: 2019-09-13
Time: 8:45-17:00 Pacific Time
Registration fee: (USD): Regular: $195; Academic: $125; For unemployed or students: $30; For major-sponsor rep (incl lunch): $0; For vendor-show rep: $35
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor: (1)Almac;(Major Sponsorship - afternoon session still open)
Vendor show vendors registered to date: (10)Celerion; CMIC, Inc.; Intertek; Labcorp; MicroConstants; Pharmaron; PRIMERA ANALYTICAL SOLUTIONS CORP; Promethera Biosciences; QPS, LLC; Waters Corporation
Registration: http://www.PBSS.org
Registration deadline:2019-09-11  (it will close sooner if the seating cap is reached)

About the Topic

​Biotransformation of small molecules is intensively investigated during drug discovery and development stages. In contrast, biotransformation of larger molecules such as antibodies, proteins, antibody-drug conjugates, peptides and nucleotides has been less emphasized. In the last decade, there have been increasing interests and expertise in understanding of larger molecule biotransformation and disposition. This workshop will cover this topic for diverse therapeutics and provide an opportunity for the community to discuss the technical aspect, role and impact of biotransformation for development of larger molecule therapeutics.

Key topics:

  • Introduction to Disposition and Biotransformations of Larger Molecules 
  • Biotransformation and Trafficking of Peptide Therapeutics
  • Biotransforamtion and biodistribution of Oligonucleotide Therapeutics 
  • Biotransformation of Antibody Therapeutics
  • Biotransformation of Next-generation ADCs
  • Tissue Disposition of Protein and Antibody Therapeutics

 

Agenda

8:45  Workshop welcome

8:45-9:30  Donglu Zhang (Genentech): Distribution and Disposition of Larger Molecule Drugs: Local Metabolism and Local Concentration

9:30-10:15  Mark Cancilla (Merck): Developing Peptide Therapeutics By Understanding Their Metabolism And Trafficking

10:15-10:30  Morning Break

10:30-11:15  Aiming Yu (UC Davis): Bioengineered RNAi Prodrug: Production, Biotransformation and Efficacy

11:15-11:50  Jing Li (Alnylam Pharmaceuticals): Understanding the Biotransformation of RNAi Therapeutics Using High Resolution Mass Spectrometry

11:50-12:25  Fang Xie (Amgen): Biotransformation of siRNA Therapeutics

12:25-1:20  Lunch

1:20-2:00  Mei Han (Amgen): Biotransformation Study for Protein and Antibody Therapeutics Using Immunoaffinity Purification Capillary Electrophoresis Mass Spectrometry (IA-CE-MS)

2:00-2:35  Srikanth Kotapat (Bristol-Myers Squibb): The Role of LC-MS in In Vivo Biotransformation Assessment of Therapeutic Proteins

2:35-3:10  Dian Su (Genentech): Advanced Strategies, Technologies and Applications in ADC Biotransformation

3:10-3:25 Afternoon Break

3:25-4:05  Ben Shen (Genentech): Considerations and Approaches in Determining Tissue Disposition of Biotherapeutics and Impact on Drug Development

4:05-4:45  Divya Samineni (Genentech): Impact of PBPK Modeling on Polatuzumab Vedotin Labeling – Waiver for Clinical DDI Studies

4:45-5:15 Panel discussion: all speakers/topics

Workshop ends by 5:15pm


2024-04-12, [Free Online] Innovative Life Science Technologies in the Drug Development Toolbox: From Cancer Organoids and Biomarker Profiling to Label-Free Multiplex QES Assays
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-05-30, [Online Workshop] Career Transition for Research Scientists
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
©Pharmaceutical & BioScience Society, International; Last Modified: 3/29/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Lena Biosciences Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
Submit a Text Ad